Global Information
회사소개 | 문의 | 비교리스트

세계의 단일클론항체 시장 : 성장 동향, COVID-19의 영향 예측(2021-2026년)

Monoclonal Antibodies Market - Growth, Trends, COVID-19 Impact, and Forecast(2022 - 2027)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2022년 01월 상품코드 1020419
페이지 정보 영문 배송안내 2-3일 (영업일 기준)
가격
US $ 4,750 ₩ 6,176,000 PDF (Single User License)
US $ 5,250 ₩ 6,827,000 PDF (Team License: Up to 7 Users)
US $ 6,500 ₩ 8,452,000 PDF (Site License)
US $ 8,750 ₩ 11,378,000 PDF (Corporate License)


세계의 단일클론항체 시장 : 성장 동향, COVID-19의 영향 예측(2021-2026년) Monoclonal Antibodies Market - Growth, Trends, COVID-19 Impact, and Forecast(2022 - 2027)
발행일 : 2022년 01월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 단일클론항체 시장 규모는 2021-2026년의 예측 기간 동안 8.51%의 CAGR 성장이 예상됩니다.

COVID-19 유행에 따라 단일클론항체의 생산을 중단됐으며 암이나 유전자 치료에 널리 사용되고 있기 때문에 세계의 단일클론항체 시장에 심각한 영향을 미쳤습니다. COVID-19이 2020년 유럽과 미국에서 정점에 도달했을 때 COVID-19 치료를 위한 새로운 단일클론항체 치료법에 종사하고있는 기업은 거의 없었습니다. 그들은 회복한 사람에게서 COVID-19 항체를 분리하고 COVID-19 감염의 치료로 이들을 시험했고 그 결과 성공하여 미국 식품 의약품 안전청에 의해 긴급 사용 승인되었습니다. 예를 들어, 2021년 2월 식품 의약품 안전청은 경도에서 중등도의 COVID-19 감염 환자를 위해 Eli Lilly and Company가 개발한 Bamlanivimab과 etesevimab의 병용 요법 긴급 사용을 허가했습니다. 또한 단일클론항체 응용 가능성이 있어 COVID-19 단일클론항체의 세계 시장을 촉진할 것으로 기대됩니다.

단일클론항체는 선진국의 다양한 형태의 암 치료에 편재되어 세계의 단일클론항체 시장의 급속한 성장에 기인하고 있습니다. GOLOBOCAN 2020 보고서에 따르면 세계에서 1,930만 명의 신규 암 증례와 약 1,000만명의 암으로 인한 사망 암 증례 증가가 시장의 주요 성장 요인입니다. 세계의 단일클론항체 시장의 높은 성장에 적극적으로 공헌하며 다른 요인은 새로운 유전자 기반 치료, COVID-19 같은 기타 일부 치명적인 질병 치료의 단일클론항체 적용, 관련 새로운 연구, 질병 진단 및 자가 면역, 바이러스성 질환 치료와 같은 기타 질환입니다. 또한 정부의 새로운 항체 승인도 시장 성장에 도움이 됩니다. 예를 들어 2020년 7월, Union Chimique Belge(UCB)는 진행성 핵 상성 마비(PSP) 및 알츠하이머 병 치료를 위해 강력한 단일클론항체인 UCB0107의 생산 및 상업 생산에 대해 Roche 및 Genentech와 라이센스 계약을 체결했습니다. 그러나 아직 조사 단계에 있습니다.

단일클론항체 비용은 그 복잡한 제조 과정과 연구 개발에 따른 비용으로 인해 매우 높고, 세계의 단일 클론 항체 시장 성장을 방해하는 주요 요인 중 하나입니다. 단일클론항체의 높은 비용 탓에 아직도 선진국에만 보급되고 있으며, 개발 도상국에서 보급되지 않는 주된 이유입니다. 시장을 억제하는 또 다른 요인은 기업 특허 상실입니다.

단일클론항체(Monoclonal Antibodies) 시장을 조사했으며, 시장 개요, 시장 성장 요인 및 저해 요인 분석, 시장 기회, COVID-19의 영향, 제조 방법·재료·적응증, 최종 사용자, 지역별 시장 규모 추이 및 예측, 경쟁 상황, 주요 기업 개요 등 체계적인 정보를 제공합니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 시장 역학

  • 시장 개요
  • 시장 추진력
    • 기술 진보 증가
    • 암 및 기타 만성 질환 부담 증가
    • 연구 개발에 대한 정부의 거액 자금
  • 시장 억제 요인
    • 단일클론항체 생산 방법에 대한 높은 비용
    • 특허 상실
  • 포터의 5세력 모형

제5장 시장 세분화

  • 제조 방법별
    • 생체
    • 시험관
  • 원료별
    • 키메라
    • 인간
    • 인간화
  • 적응증별
    • 자가 면역질환
    • 감염
    • 염증성 질환
    • 기타
  • 최종 사용자별
    • 병원
    • 조사 기관
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양 지역
    • 중동과 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 프로필
    • Eli Lilly and Company
    • Johnson&Johnson
    • Merck KGaA
    • Pfizer, Inc.
    • GlaxoSmithKline PLC
    • Novartis AG
    • AstraZeneca PLC
    • Amgen, Inc.
    • AbbVie, Inc.
    • Bristol Myers Squibb Co.

제7장 시장 기회와 동향

NJH 21.08.09

The monoclonal antibodies market is expected to register a CAGR of 8.51% during the forecast period of 2021-2026.

The monoclonal antibody production was halted due to the COVID-19 pandemic, and it severely affected the global monoclonal antibodies market as they are widely used in cancer and gene therapy, thus affecting the global monoclonal antibodies market. Although COVID-19 was at its peak in Europe and the United States in 2020, few companies were working on new therapy based on monoclonal antibodies to treat COVID-19. They isolated the COVID-19 antibodies from a recovered person and tested them as a cure for COVID-19 infection, and they were successful and got approval for emergency use by the United States Food and Drug Administration. For example, in February 2021, the Food and Drug Administration permitted emergency use of combined bamlanivimab and etesevimab therapy developed by Eli Lilly and Company for people with mild to moderate COVID-19 infection. Moreover, due to the potential application of monoclonal antibodies, it can be expected that COVID-19 will promote the global market of monoclonal antibodies.

The monoclonal antibodies are becoming ubiquitous in the treatment of different forms of cancer in developed countries, and this has been attributed to the rapid growth of the global monoclonal antibodies market. According to the report of GOLOBOCAN 2020, there were 19.3 million new cases of cancer and about 10 million deaths due to cancer in the world, and increasing cancer cases are the major growth factor behind the market. The other factors, which may contribute positively toward the high growth of the global monoclonal antibodies market, are new gene-based therapy, new research related to the application of monoclonal antibodies in treating some other deadly diseases, like COVID-19, disease diagnostics, and treatment of other diseases, like auto-immune, viral disease treatment, and also the approval of new antibodies by governments may lead to the growth of the market. For instance, in July 2020, Union Chimique Belge (UCB) did a license agreement with Roche and Genentech for the manufacturing and commercial production of UCB0107, which is a potent monoclonal antibody for the treatment of progressive supranuclear palsy (PSP) and Alzheimer's disease, but it is still under investigation.

The cost associating with monoclonal antibodies is very high because of their complex manufacturing procedure and due to the cost involved in R&D, and it is one of the major restraining factors for the growth of the global monoclonal antibodies market. The high cost of monoclonal antibodies is the main reason why it is still prevalent only in developed countries and not in developing and underdeveloped countries. Another factor responsible that can prove a restraint for this market will be the loss of patents by companies.

Key Market Trends

Cancer Monoclonal Antibodies is Estimated to Occupy a Significant Share in the Market over the Forecast Period

According to the World Health Organization, cancer is the leading cause of death globally. As per the GLOBOCAN 2020 report, there were around 19.3 new cancer cases and about 10 million deaths due to cancer worldwide in 2020, and the most common types of cancer were breast cancer, followed by lung cancer, rectal cancer, prostate cancer, and others. Due to the rising prevalence of cancer cases, globally, in the global monoclonal antibodies market, cancer monoclonal antibodies may occupy a major market share.

Additionally, the global pharmaceutical companies are investing heavily in the R&D of cancer biologics drugs (monoclonal antibodies), because they are very efficient and non-toxic in the diagnostics and treatment of different types of cancer as compared to chemotherapy and other cancer treatment methods. Moreover, getting approvals for many new cancer monoclonal antibodies by the respective governments is more efficient and easy. According to an article published in December 2019 in Taylor & Francis Online, about 5 antibody therapeutics were provided first approval in either European Union or the United States, and these include romosozumab, risankizumab, polatuzumab vedotin, brolucizumab, and crizanlizumab. Polatuzimab vedotin (Polivy) was granted conditional marketing authorization in November 2019 for the treatment of relapsed /refractory diffuse large B-cell lymphoma. In another instance, in December 2020, the United States Food and Drug Administration approved MacroGenics' MARGENZATM for the treatment of patients with pretreated metastatic HER2-positive breast cancer. These advancements may fuel the growth of the monoclonal antibodies market.

North America is Expected to Dominate the Global Monoclonal Antibodies Market during the Forecast Period

North America is segmented into three countries - the United States, Canada, and Mexico. North America may dominate in the market share of global monoclonal antibodies because of the presence of standard nationwide healthcare system, especially in the United States and Canada, huge funding by governments for the R&D of new biological therapies, especially for cancer and new infectious diseases, rising geriatric population and diseases associated with them, and presence of key market players in the region during the forecast period. For example, in November 2020, the Government of Canada and Eli Lilly signed an agreement for a monoclonal antibody therapy called Bamlanivimab (LY-CoV555) for COVID-19 developed by Eli Lilly Company, a total of 26,000 doses were ordered initially.

Some of the key market players are headquartered in the United States, actively advancing the technique, launching new products, and forming strategic partnerships to have an edge in the monoclonal antibodies market. The government's National Institute of Health and other related organizations are also engaged in the development of monoclonal antibodies and, over the year, had few breakthroughs. For instance, in August 2020, the National Institute of Health announced the launch of a clinical trial for two potential treatments of COVID-19 by using monoclonal antibodies. Additionally, the increasing cases of chronic diseases, such as cancer, may boost the growth of the market in the region. As per the GLOBOCAN 2020 report, 2,281,658 new cancer cases were diagnosed and 612,390 deaths due to cancer in the United States alone. The cancer cases in Canada and Mexico were 274,364 and 195,499, respectively. These factors are expected to drive the growth of the studied market over the forecast period.

Competitive Landscape

The global monoclonal antibodies market is expected to be highly competitive with the number of established companies in the market and the new incoming companies, which are investing heavily in R&D with new and advanced technologies. In the current scenario, COVID-19 and cancer therapeutics are expected to be the major domain of competition between the companies. Some of the major key players of the global monoclonal antibodies market are - Eli Lilly, F Hoffmann-La Roche, Merck, Amgen Inc., and Novartis AG, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Technological Advancements
    • 4.2.2 Increasing Burden of Cancer and Other Chronic Diseases
    • 4.2.3 Huge Funding by Government for the Research and Development
  • 4.3 Market Restraints
    • 4.3.1 High Cost Pertaining to the Method Involved in the Production of Monoclonal Antibodies
    • 4.3.2 Loss of Patents
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers/Consumers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Production Methods
    • 5.1.1 In Vivo
    • 5.1.2 In Vitro
  • 5.2 By Source
    • 5.2.1 Chimeric
    • 5.2.2 Human
    • 5.2.3 Humanized
    • 5.2.4 Murine
  • 5.3 By Indications
    • 5.3.1 Cancer
    • 5.3.2 Autoimmune Diseases
    • 5.3.3 Infectious Diseases
    • 5.3.4 Inflammatory Diseases
    • 5.3.5 Other Indications
  • 5.4 By End Users
    • 5.4.1 Hospitals
    • 5.4.2 Research Institutes
    • 5.4.3 Other End Users
  • 5.5 By Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia Pacific
    • 5.5.4 Middle-East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Eli Lilly and Company
    • 6.1.2 Johnson & Johnson
    • 6.1.3 Merck KGaA
    • 6.1.4 Pfizer Inc.
    • 6.1.5 GlaxoSmithKline PLC
    • 6.1.6 Novartis AG
    • 6.1.7 AstraZeneca PLC
    • 6.1.8 Amgen Inc.
    • 6.1.9 AbbVie Inc.
    • 6.1.10 Bristol Myers Squibb Co.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q